TYMS and breast carcinoma: We then confirmed that thymidylate synthase inhibition sensitized to navitoclax in additional diverse cell lines including ZR75 (breast cancer), A549 (lung adenocarcinoma), A375P (melanoma), and RKO (colon cancer) (Fig. 4h).